GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Veru Inc (STU:FMW) » Definitions » Total Liabilities

Veru (STU:FMW) Total Liabilities : €24.46 Mil (As of Mar. 2024)


View and export this data going back to 2019. Start your Free Trial

What is Veru Total Liabilities?

Veru's Total Liabilities for the quarter that ended in Mar. 2024 was €24.46 Mil.

Veru's quarterly Total Liabilities declined from Sep. 2023 (€28.43 Mil) to Dec. 2023 (€26.56 Mil) and declined from Dec. 2023 (€26.56 Mil) to Mar. 2024 (€24.46 Mil).

Veru's annual Total Liabilities increased from Sep. 2021 (€21.98 Mil) to Sep. 2022 (€53.09 Mil) but then declined from Sep. 2022 (€53.09 Mil) to Sep. 2023 (€28.43 Mil).


Veru Total Liabilities Historical Data

The historical data trend for Veru's Total Liabilities can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Veru Total Liabilities Chart

Veru Annual Data
Trend Sep14 Sep15 Sep16 Sep17 Sep18 Sep19 Sep20 Sep21 Sep22 Sep23
Total Liabilities
Get a 7-Day Free Trial Premium Member Only Premium Member Only 19.34 18.20 21.98 53.09 28.43

Veru Quarterly Data
Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
Total Liabilities Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 50.00 37.67 28.43 26.56 24.46

Veru Total Liabilities Calculation

Total Liabilities are the liabilities that the company has to pay others. It is a part of the balance sheet of a company that shareholders do not own, and would be obligated to pay back if the company liquidated.

Veru's Total Liabilities for the fiscal year that ended in Sep. 2023 is calculated as

Total Liabilities=Total Current Liabilities+Total Noncurrent Liabilities
=Total Current Liabilities+(Long-Term Debt & Capital Lease Obligation+Other Long-Term Liabilities
=16.689+(11.716+0.028
+NonCurrent Deferred Liabilities+PensionAndRetirementBenefit)
+0+0)
=28.43

Total Liabilities=Total Assets (A: Sep. 2023 )-Total Equity (A: Sep. 2023 )
=46.872-18.438
=28.43

Veru's Total Liabilities for the quarter that ended in Mar. 2024 is calculated as

Total Liabilities=Total Current Liabilities+Total Noncurrent Liabilities
=Total Current Liabilities+(Long-Term Debt & Capital Lease Obligation+Other Long-Term Liabilities
=8.801+(11.075+4.588
+NonCurrent Deferred Liabilities+PensionAndRetirementBenefit)
+0+0)
=24.46

Total Liabilities=Total Assets (Q: Mar. 2024 )-Total Equity (Q: Mar. 2024 )
=66.056-41.593
=24.46

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Veru Total Liabilities Related Terms

Thank you for viewing the detailed overview of Veru's Total Liabilities provided by GuruFocus.com. Please click on the following links to see related term pages.


Veru (STU:FMW) Business Description

Traded in Other Exchanges
Address
2916 North Miami Avenue, Suite 1000, Miami, FL, USA, 33127
Veru Inc is a biopharmaceutical company with a drug development program for the treatment of metabolic diseases, oncology and acute respiratory distress syndrome (ARDS). The company is also in the late stage development of certain drugs for management of breast and prostate cancers. It also has a sexual health program which includes two products, ENTADFI, for the treatment of benign prostatic hyperplasia (BPH) and the FC2 Female Condom (Internal Condom). The company operates in single segment and generates revenue from USA which is the key revenue generating market, South Africa and other regions.

Veru (STU:FMW) Headlines

No Headlines